SECTION 3 – 510(k) SUMMARY

DATE PREPARED: September 17, 2010

OWNER/OPERATOR:
Firm: Hologic, Inc.
Address: 6100 Technology Center Drive
Indianapolis, IN 46278
Phone #: 317-344-7500
Fax #: 317-344-7697
Registration #: 3003862400

CONTACT: Primary Contact from September 20-October 1
Heidi Strunk
Director, Quality and Regulatory Affairs
Hologic, Inc.
6100 Technology Center Drive
Indianapolis, IN 46278
Phone: 317-344-7630
E-mail: heidi.strunk@hologic.com

Primary Contact after October 1
Alyssa M. Lobo
Senior Quality and Regulatory Consultant (a full-time employee of Hologic, Inc.)
Hologic, Inc.
6100 Technology Center Drive
Indianapolis, IN 46278
Phone: 317-344-7532
E-mail: alyssa.lobo@hologic.com

DEVICE NAME:
Classification Name: Marker, Implantable Radiographic
Common/Usual Name: Tissue Site Marking System
Proprietary Name: SecurMark Biopsy Site Marking System
Device Class: Class II
Description: Implantable Clip
Number: NEU
21 CFR Ref: 878.4300
Performance Standard: None established
Section 3.1 – Description of the Device

The SecurMark Biopsy Site Markers provide the user with the ability to mark the location of the cavity where a breast biopsy was performed. Radiographic marking allows physicians to locate biopsy cavities should a follow-up lumpectomy or re-biopsy be necessary.

The SecurMark Biopsy Site Marker is a sterile, single patient use device comprised of a single, permanent biocompatible titanium or stainless steel marker surrounded by a bioabsorbable suture-like material and a deployment device.

The deployment device consists of a rigid cannula, handle, rigid push rod, spring, and plunger. The marker is located at the distal end of the deployment device. The marker is used in conjunction with a biopsy device. The biopsy devices available for use with the SecurMark markers are offered in different needle gauge sizes and lengths. In order to be compatible with their respective biopsy devices, the biopsy site marker deployment devices may be available in multiple size offerings.

The hand-held deployment device is utilized for both introducing the marker into the breast and depositing the marker into the biopsy cavity. The deployment device is manually operated and has limited contact with the patient. After the physician has appropriately positioned the deployment device, the physician manually depresses the plunger of the deployment device to deposit the marker in the intended location.

The permanent marking components of the SecurMark Biopsy Site Markers are available in different geometric shapes. In the event that two or more biopsy sites need to be marked, the user has the option to use a different shape of marker in each biopsy location. Each marker shape can be discerned under stereotactic (x-ray) imaging.

The permanent markers are classified as magnetic resonance (MRI) conditional at 3.0 Tesla field strength or less. The marker, when present in a patient undergoing an MRI procedure at 3.0 Tesla or less, will not create an additional hazard or risk with respect to magnetic field-related interactions, movement/dislodgement or heating.

The SecurMark Biopsy Site Markers should be used only by physicians trained in open or percutaneous biopsy procedures.
Section 3.2 – Intended Use

The SecurMark Biopsy Site Marking System is intended for use with the manual method of deployment. It can be visualized under various imaging modalities such as ultrasound, x-ray, magnetic resonance, direct visualization, and others. This system is intended for single patient use only. The Tissue Site Marking System is indicated for the permanent radiographic marking of sites in soft tissue.

Section 3.3 – Description of Device Modification

The modifications that are the subject of this 510(k) submission are as follows:

Modification to Permanent Marking Component Shape
The biopsy site markers that were cleared in K062528 specified markers that were cylindrical or “bow tie” shaped. The marking components that are the subject of this submission are shaped in one-hole, two-hole, or three-hole designs. See Section 3.5 for illustrations of the different marker shapes.

Modifications to Instructions for Use (IFU)
The Instructions for Use for the SecurMark Biopsy Site Markers that were cleared in K062528 address use of the biopsy site marker device only with other Hologic devices.

It has come to Hologic's attention that users who place Hologic biopsy site markers under ultrasound guidance sometimes utilize other non-Hologic biopsy devices and accessories, such as an introducer, (also referred to as a coaxial), prior to placement of the markers. Hologic's current IFU does not address the use of the biopsy site markers with any other company's biopsy devices and/or accessories.

In order to further guide users on the safe use of the Hologic biopsy site marker device, the proposed Instructions for Use has been modified to provide information to users regarding the dimensions of other devices that may be compatible with Hologic's biopsy site markers. The proposed new Instructions for Use are provided in Section 4.2.
### Section 3.4 – Comparison of 510(k) Cleared Tissue Site Marking Systems

<table>
<thead>
<tr>
<th></th>
<th>SecurMark Biopsy Site Marking System (this 510(k) application)</th>
<th>Tissue Site Marking System K062528 (cleared)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indicated Use</strong></td>
<td>The Tissue Site Marking System is indicated for the permanent</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td></td>
<td>radiographic marking of sites in soft tissue.</td>
<td>C</td>
</tr>
<tr>
<td><strong>Bioabsorbable Marker</strong></td>
<td>Glycoprene II® Monofilament (PLA/PGA)</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Material</strong></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td><strong>Permanent Marker</strong></td>
<td>Titanium (Grade 2) or 316 Stainless Steel</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Material</strong></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td><strong>Supplied Sterile</strong></td>
<td>YES</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Sterilization Method</strong></td>
<td>Gamma Irradiation</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Sterilization Dose</strong></td>
<td>25kGy-50kGy</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Sterility Assurance</strong></td>
<td>$10^6$</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Level (SAL)</strong></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td><strong>Single Patient Use</strong></td>
<td>YES</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Deployment Device</strong></td>
<td>Cannula: Stainless Steel, Titanium, or similar materials</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Materials</strong></td>
<td>Handle: Polycarbonate or similar materials</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td></td>
<td>Spring: Stainless Steel or Beryllium Copper</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Deployment Device</strong></td>
<td>Manufactured by Hologic, Inc.</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Manufacturing Methods</strong></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td><strong>Packaging Materials</strong></td>
<td>High Impact Polystyrene (HIPS) Tray and foil pouch</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Shelf Life</strong></td>
<td>1 Year</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Method of Marker</strong></td>
<td>Manual</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Deployment</strong></td>
<td></td>
<td>C</td>
</tr>
<tr>
<td><strong>Dimensions</strong></td>
<td><strong>Deployment Device</strong> Overall Length: 5.934”</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td></td>
<td><strong>Bioabsorbable Marker</strong> Length: 0.591”</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td></td>
<td>Center Diameter: 0.110”</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td></td>
<td>Closure Diameter: 0.044”</td>
<td>IDENTICAL</td>
</tr>
<tr>
<td><strong>Permanent Marker Shapes</strong></td>
<td>(See Section 3.5 Device Illustrations for images)</td>
<td></td>
</tr>
<tr>
<td>1st Shape</td>
<td>One-hole</td>
<td>Cylinder</td>
</tr>
<tr>
<td>2nd Shape</td>
<td>Two-hole</td>
<td>“Bow tie”</td>
</tr>
<tr>
<td>3rd Shape</td>
<td>Three-hole</td>
<td>Item not available</td>
</tr>
</tbody>
</table>
Section 3.4 – Comparison of 510(k) Cleared Tissue Site Marking Systems, continued

<table>
<thead>
<tr>
<th>Permanent Marker Dimensions</th>
<th>SecurMark Biopsy Site Marking System (this 510(k) application)</th>
<th>Tissue Site Marking System K062528 (cleared)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Shape</td>
<td>Length: 0.100” Width: 0.037” Thickness: 0.010”</td>
<td>Length: 0.070” Diameter: 0.036”</td>
</tr>
<tr>
<td>2nd Shape</td>
<td>Length: 0.087” Width: 0.037” Thickness: 0.010”</td>
<td>Length: 0.075” Width: 0.036” Height: 0.036”</td>
</tr>
<tr>
<td>3rd Shape</td>
<td>Length: 0.094” Width: 0.037” Thickness: 0.010”</td>
<td>Item not available</td>
</tr>
</tbody>
</table>

Similarities between device and legally marketed devices
The similarities between the subject of the 510(k) submission and the previously cleared 510(k) device include:
1. Indications for Use
2. Intended Use
3. Scientific technology
4. Sterilization dose and method
5. Deployment device materials
6. Marker Materials
7. Deployment device manufacturing site and methods
8. Biocompatibility
9. Shelf Life
10. Supplied sterile for single patient use

Differences between device and legally marketed devices
Currently, the SecurMark Biopsy Site Identification system that is cleared under K062528 is different from the subject of this 510(k) application only in that:
1) The permanent marker components from K062528 are available in two shapes: cylinder and "bow tie." The markers that are the subject of this application are available in three shapes that feature one, two, or three openings.
2) The Instructions for Use for the currently marketed biopsy site markers do not provide users with any language to provide guidance if a customer chooses to use a non-Hologic introducer (co-axial) when placing the biopsy site marker under ultrasound visualization.

The new permanent marker shapes provide users with additional options for marking biopsy site locations. Each new shape is discernable from the other new shapes and from other Hologic marker shapes. The new wording in the IFU will give general guidance to users if they choose not to use a Hologic introducer when placing a Hologic biopsy site marker under ultrasound.

All other aspects of the subject of this 510(k) submission are the same as the legally marketed devices. No changes are made in the intended use or the fundamental scientific principles of the previously cleared devices.

Conclusion
Based on the information presented in this Special 510(k) submission, the SecurMark Biopsy Site Marking System is substantially equivalent to the presently marketed Hologic, Inc. Tissue Site Marking System (K062528). No new safety or efficacy questions are raised with the SecurMark Biopsy Site Marking System that is the subject of this submission.
Section 3.5 - Device Illustrations

Assembled Deployment Device
Identical to the deployment device cleared in K062528

<table>
<thead>
<tr>
<th>Device</th>
<th>Overall Cannula Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMark-U-ss1</td>
<td>5.934&quot;</td>
</tr>
<tr>
<td>SMark-U-ss2</td>
<td>5.934&quot;</td>
</tr>
<tr>
<td>SMark-U-ss3</td>
<td>5.934&quot;</td>
</tr>
</tbody>
</table>

Deployment Device (K062528)
Plunger: Pebax
Push Rod: Stainless Steel or Titanium
Spring: Stainless Steel or Beryllium Copper
Handle: Polycarbonate or similar materials
Cannula: Stainless Steel, Titanium, or similar materials

The marker is loaded into the distal end of the deployment device during the manufacturing process.

Marker (Cleared in K062528)
Bioabsorbable Component – PLA/PGA (Glycoprene II)
Permanent Component – 316 Stainless Steel or Titanium
### Section 3.5 – Device Illustrations, continued

<table>
<thead>
<tr>
<th>Permanent Marker Images</th>
<th>SecurMark Biopsy Site Marking System (this 510(k) application)</th>
<th>Tissue Site Marking System K062528 (cleared)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1st Shape</strong></td>
<td><img src="image1.png" alt="One-hole" /></td>
<td><img src="image2.png" alt="Cylinder" /></td>
</tr>
<tr>
<td>2nd Shape</td>
<td><img src="image3.png" alt="Two-hole" /></td>
<td>&quot;Bow tie&quot;</td>
</tr>
<tr>
<td>3rd Shape</td>
<td><img src="image4.png" alt="Three-hole" /></td>
<td>Item not available</td>
</tr>
</tbody>
</table>

**SecurMark Biopsy Site Marking System**: Marking System

**Tissue Site Marking System K062528**: (cleared)
Section 3.6 – Stereotactic Images

The stereotactic (x-ray) image below shows the new marker shapes compared to the previously cleared SecurMark Biopsy Site Marker permanent marking components.

*FAB-05155, the new three-hole marker, has since been modified to form a "J" shape. See images on previous page for illustration.

** Previously cleared under K062528.
Section 3.7 - Packaging

Packaging Materials

<table>
<thead>
<tr>
<th>Packaging Component</th>
<th>Material</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pouch</td>
<td>RFP-048</td>
</tr>
<tr>
<td>Tray</td>
<td>White High Impact Polystyrene (HIPS)</td>
</tr>
</tbody>
</table>

Drawings of the packaging materials are included in the following pages.

After the SecurMark Biopsy Site Markers have been placed into trays and sealed in pouches, they are labeled and placed into boxes. There are ten SecurMark Biopsy Site Markers and one Instructions for Use (IFU) manual packaged in each box. Markers are sold to customers in case quantities; they are not sold individually.
## Section 3.8 – Design Control Activities Summary

<table>
<thead>
<tr>
<th>Modifications from Predicate Devices</th>
<th>Risk (from DFMEA)</th>
<th>Verification / Validation Activities</th>
<th>Acceptance Criteria</th>
<th>Results/Justification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Permanent marker components are shaped differently than those cleared in K062528</td>
<td>Product Performance</td>
<td>X-ray testing</td>
<td>New marker shapes must be discernable from other new marker shapes and current Hologic SecurMark marker shapes</td>
<td>Met acceptance criteria</td>
</tr>
<tr>
<td></td>
<td>Product Performance (deployment of marker)</td>
<td>Simulated use</td>
<td>Deployment device must accommodate marker and deploy marker as intended.</td>
<td>Met acceptance criteria</td>
</tr>
<tr>
<td>IFU has been updated to provide general guidance for use of the biopsy site marker with non-Hologic introducer (coaxial) devices</td>
<td>Incompatible geometries</td>
<td>Tolerance analysis</td>
<td>Biopsy Site Marker must be able to be inserted into an introducer (coaxial) with specific minimum and maximum dimensions</td>
<td>Minimum introducer (coaxial) cannula inner diameter dimension established. Maximum introducer (coaxial) cannula length established.</td>
</tr>
<tr>
<td></td>
<td>Product Performance</td>
<td>Simulated Use</td>
<td>Biopsy site marker deployment device must be geometrically compatible with introducers (coaxial) that meet the length and diameter criteria set by the Tolerance Analysis</td>
<td>Hologic biopsy devices tested with multiple introducer (coaxial) devices. Biopsy Site Markers met acceptance criteria</td>
</tr>
</tbody>
</table>

No new safety or efficacy questions are raised with the SecurMark Biopsy Site Marking System that is the subject of this submission.
Hologic, Inc.
% Ms. Alyssa M. Lobo
Senior Quality and Regulatory Consultant
6100 Technology Center Drive
Indianapolis, Indiana 46278

Re: K102768
Trade/Device Name: Biopsy Site Marking System
Regulation Number: 21 CFR 878.4300
Regulation Name: Implantable clip
Regulatory Class: I
Product Code: NEU
Dated: November 11, 2010
Received: November 23, 2010

Dear Ms. Lobo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical
device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for
the Center for Devices and Radiological Health’s (CDRH’s) Office of Compliance. Also, please
note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR Part
807.97). For questions regarding the reporting of adverse events under the MDR regulation (21
CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office
of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the
Division of Small Manufacturers, International and Consumer Assistance at its toll-free number
(800) 638-2041 or (301) 796-7100 or at its Internet address

Sincerely yours,

Mark M. Melkerson
Director
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure
SECTION 2 - STATEMENT OF INDICATIONS FOR USE

Indications for Use

510(k) Number (if known): K102768

Device Name: Biopsy Site Marking System

Indications for Use: The Tissue Site Marking System is indicated for the permanent radiographic marking of sites in soft tissue.

Prescription Use _x_ (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter-Use__ (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)